Agitation and hyperarousal are among the most distressing symptoms of Alzheimer’s disease—impacting patients, caregivers, and overall quality of life.

Until recently, treatment options were limited and often relied on off-label use of antipsychotics, which carry significant risks in older adults.

Now, a novel approach is emerging: Auvelity (dextromethorphan–bupropion) is gaining attention—and has received recent FDA approval for agitation in Alzheimer’s disease—marking a major shift in treatment strategy.

Most conversations around nutrition focus on calories, macros, or food quality. But an emerging field—chrono-nutrition—is showing that meal timing may be just as important for mental health as what’s on your plate.

For patients in Reno, Nevada, struggling with anxiety, poor sleep, low energy, or burnout, this is a critical (and often overlooked) piece of the puzzle.

Glucagon-like peptide-1 (GLP-1) receptor agonists—like semaglutide and liraglutide—are widely known for treating type 2 diabetes and obesity.

But emerging research is shifting the conversation. These medications may also modulate reward pathways in the brain, offering a novel, biologically grounded approach to addiction, compulsive behaviors, and psychiatric symptoms.

For patients in Reno, Nevada, this represents a potential paradigm shift in how we approach treatment-resistant patterns like binge eating, alcohol use, and even certain behavioral addictions.

Brain fog, sleep disruption, chronic stress Reno, NV

Depression treatment in Reno, NV.